ReviewClinical microbiology reviews2008
Current status of vaccines for schistosomiasis.
Review in Clinical microbiology reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Implications of Changing Temperatures on the Growth, Fecundity and Survival of Intermediate Host Snails of Schistosomiasis: A Systematic Review.International journal of environmental research and public health · 2017Pooled it
- Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis.PloS one · 2012Pooled it
- Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis.Parasites & vectors · 2011Pooled it
- A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area.PLoS neglected tropical diseases · 2023Trial
- Trial
- Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- Revisiting immunity vs. exposure in schistosomiasis: A mathematical modeling study of delayed concomitant immunity.PNAS nexus · 2024Article
- The efficacy of cercarial antigen loaded on nanoparticles as a potential vaccine candidate inJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Transmission-Blocking Vaccines against Schistosomiasis Japonica.International journal of molecular sciences · 2024Review
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
- Evolution of tetraspanin antigens in the zoonotic Asian blood fluke Schistosoma japonicum.Parasites & vectors · 2023Article
- Preparation of polyclonal anti-Schistosoma mansoni cysteine protease antibodies for early diagnosis.Applied microbiology and biotechnology · 2023Article
- Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice.NPJ vaccines · 2023Article
- Anti-schistosomal immunity to core xylose/fucose in N-glycans.Frontiers in molecular biosciences · 2023Article
- The Indispensability of Snail Control for Accelerating Schistosomiasis Elimination: Evidence from Zanzibar.Tropical medicine and infectious disease · 2022Article
- Dynamics in Morbidity Markers and Cytological Observations Made in Urine ofMedical sciences (Basel, Switzerland) · 2022Article
- De Novo Design of Cathepsin B1 Inhibitors as Potential Anti-Schistosomal Agents Using Computational Studies.Advances and applications in bioinformatics and chemistry : AABC · 2022Article
- Schistosoma mansoni egg-derived extracellular vesicles: A promising vaccine candidate against murine schistosomiasis.PLoS neglected tropical diseases · 2021Article
- Review
- Review
138 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Schistosomiasis, caused by trematode blood flukes of the genus Schistosoma, is recognized as the most important human helminth infection in terms of morbidity and mortality. Infection follows direct contact with freshwater harboring free-swimming larval (cercaria) forms of the parasite. Despite the existence of the highly effective antischistosome drug praziquantel (PZQ), schistosomiasis is spreading into new areas, and although it is the cornerstone of current control programs, PZQ chemotherapy does have limitations. In particular, mass treatment does not prevent reinfection. Furthermore, there is increasing concern about the development of parasite resistance to PZQ. Consequently, vaccine strategies represent an essential component for the future control of schistosomiasis as an adjunct to chemotherapy. An improved understanding of the immune response to schistosome infection, both in animal models and in humans, suggests that development of a vaccine may be possible. This review considers aspects of antischistosome protective immunity that are important in the context of vaccine development. The current status in the development of vaccines against the African (Schistosoma mansoni and S. haematobium) and Asian (S. japonicum) schistosomes is then discussed, as are new approaches that may improve the efficacy of available vaccines and aid in the identification of new targets for immune attack.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.